CA2984010A1 - Multimeric protein purity determination - Google Patents

Multimeric protein purity determination Download PDF

Info

Publication number
CA2984010A1
CA2984010A1 CA2984010A CA2984010A CA2984010A1 CA 2984010 A1 CA2984010 A1 CA 2984010A1 CA 2984010 A CA2984010 A CA 2984010A CA 2984010 A CA2984010 A CA 2984010A CA 2984010 A1 CA2984010 A1 CA 2984010A1
Authority
CA
Canada
Prior art keywords
ligand
homodimer
subunit
seq
capillary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2984010A
Other languages
English (en)
French (fr)
Inventor
Kathir MUTHUSAMY
Jiann-Kae LUO
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CA2984010A1 publication Critical patent/CA2984010A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2201/00—Features of devices classified in G01N21/00
    • G01N2201/06—Illumination; Optics
    • G01N2201/061—Sources
    • G01N2201/06113—Coherent sources; lasers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
    • G01N27/44721—Arrangements for investigating the separated zones, e.g. localising zones by optical means
    • G01N27/44726—Arrangements for investigating the separated zones, e.g. localising zones by optical means using specific dyes, markers or binding molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G01N27/44795—Isoelectric focusing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2984010A 2015-05-12 2016-05-11 Multimeric protein purity determination Pending CA2984010A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562160341P 2015-05-12 2015-05-12
US62/160,341 2015-05-12
PCT/US2016/031899 WO2016183222A1 (en) 2015-05-12 2016-05-11 Multimeric protein purity determination

Publications (1)

Publication Number Publication Date
CA2984010A1 true CA2984010A1 (en) 2016-11-17

Family

ID=56072452

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2984010A Pending CA2984010A1 (en) 2015-05-12 2016-05-11 Multimeric protein purity determination

Country Status (10)

Country Link
US (3) US10520511B2 (https=)
EP (2) EP3885368A1 (https=)
JP (3) JP7240812B2 (https=)
AR (1) AR104610A1 (https=)
AU (2) AU2016261854B2 (https=)
CA (1) CA2984010A1 (https=)
ES (1) ES2881359T3 (https=)
MA (2) MA56416A (https=)
PL (1) PL3294775T3 (https=)
WO (1) WO2016183222A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4434629A3 (en) 2015-11-30 2024-12-25 Intabio, Llc Methods for sample characterization
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
DK3668985T3 (da) 2017-08-17 2021-09-20 Just Evotec Biologics Inc Fremgangsmåde til rensning af glycosyleret protein fra værtscellegalectiner og andre urenheder
CA3081094A1 (en) 2017-11-20 2019-05-23 Alison J. GILLESPIE Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
WO2019148198A1 (en) 2018-01-29 2019-08-01 Intabio, Inc. Devices, methods and kits for sample characterization
EP3811397B1 (en) 2018-05-31 2024-09-18 Intabio, Llc Methods for interfacing microfluidic systems with mass spectrometry
PL3837282T3 (pl) * 2018-09-10 2026-02-16 Genentech, Inc. Układy i sposoby elektroforezy kapilarnej powinowactwa
US11573226B2 (en) 2018-09-10 2023-02-07 Genentech, Inc. Systems and methods for affinity capillary electrophoresis
US11782023B2 (en) * 2018-12-19 2023-10-10 Regeneron Pharmaceuticals, Inc. Ce-western applications for antibody development
CA3126712A1 (en) * 2019-01-31 2020-08-06 Regeneron Pharmaceuticals, Inc. Native microfluidic ce-ms analysis of antibody charge heterogeneity
US11285484B2 (en) 2019-08-12 2022-03-29 Intabio, Llc Multichannel isoelectric focusing devices and high voltage power supplies
US12594557B2 (en) 2019-08-12 2026-04-07 Intabio, Llc Isoelectric focusing devices and fixtures
EP4323761A1 (en) * 2021-04-14 2024-02-21 DH Technologies Development Pte. Ltd. Native fluorescence detection for protein analysis in capillary electrophoresis
JP2024544607A (ja) * 2021-11-25 2024-12-03 エフ． ホフマン－ラ ロシュ アーゲー 少量の抗体副産物の定量

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP385598A0 (en) * 1998-06-02 1998-06-25 Life Therapeutics Limited Purification of antibodies
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
JP4723725B2 (ja) * 1999-04-20 2011-07-13 ターゲット ディスカバリー， インコーポレイテッド 代謝経路を分析するための方法
US6818112B2 (en) * 1999-04-20 2004-11-16 Target Discovery, Inc. Protein separation via multidimensional electrophoresis
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
AUPQ743300A0 (en) * 2000-05-11 2000-06-01 Life Therapeutics Limited Separation of avian antibodies
SG106672A1 (en) 2002-03-08 2004-10-29 Asml Netherlands Bv Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
US20090134028A1 (en) * 2005-09-22 2009-05-28 Chemicals Evaluation And Research Institute Method of Estimating Effect of Test Chemical on Living Organisms
EP1803814A1 (en) * 2005-12-27 2007-07-04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Method of improving the antibody selection capacity in phage-display library
US9670269B2 (en) * 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
CN101874042B9 (zh) * 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
JP4977588B2 (ja) * 2007-12-07 2012-07-18 富士フイルム株式会社 イムノクロマトグラフ方法
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
CA2836873C (en) * 2011-05-21 2019-10-22 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
GB2504139B (en) 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
EP2604624A1 (en) * 2011-12-13 2013-06-19 University College Dublin National University Of Ireland, Dublin Bowman-Birk protease Inhibitor (BBI) binding peptides, and uses thereof in the separation, detection or purification of BBI.
PT2825559T (pt) * 2012-03-13 2019-06-07 Novimmune Sa Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo
RU2014153674A (ru) 2012-06-05 2016-07-27 Регенерон Фармасьютикалз, Инк. Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи
TW202423993A (zh) * 2012-11-14 2024-06-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
CA2919174A1 (en) * 2013-08-19 2015-02-26 F. Hoffmann-La Roche Ag Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography
US11261262B2 (en) * 2013-09-03 2022-03-01 Novimmune Sa Readily isolated bispecific binding molecules with native format having mutated constant regions

Also Published As

Publication number Publication date
AU2022203033B2 (en) 2025-06-26
AR104610A1 (es) 2017-08-02
US20170045527A1 (en) 2017-02-16
JP2022171730A (ja) 2022-11-11
ES2881359T3 (es) 2021-11-29
JP2018528389A (ja) 2018-09-27
PL3294775T3 (pl) 2021-12-13
JP7137663B2 (ja) 2022-09-14
WO2016183222A1 (en) 2016-11-17
EP3885368A1 (en) 2021-09-29
US20200166522A1 (en) 2020-05-28
MA43987A (fr) 2018-12-19
EP3294775B1 (en) 2021-07-14
AU2022203033A1 (en) 2022-05-26
AU2016261854B2 (en) 2022-05-26
AU2016261854A1 (en) 2017-11-09
HK1252480A1 (zh) 2019-05-24
JP2021152544A (ja) 2021-09-30
MA56416A (fr) 2022-05-04
US10520511B2 (en) 2019-12-31
US12158473B2 (en) 2024-12-03
US20240280587A1 (en) 2024-08-22
WO2016183222A4 (en) 2017-01-05
EP3294775A1 (en) 2018-03-21
JP7240812B2 (ja) 2023-03-16

Similar Documents

Publication Publication Date Title
US20240280587A1 (en) Multimeric protein purity determination
JP2021152544A6 (ja) 多量体タンパク質の純度の決定
AU2016312909B2 (en) Method for the reduction of host cell proteins in affinity chromatography
JP2018525407A (ja) 低伝導率洗浄緩衝液を用いたアフィニティークロマトグラフィー精製方法
CN113272651B (zh) 鉴别蛋白质中的游离巯基的方法
JP7527273B2 (ja) 多量体タンパク質の量および純度を決定するための方法およびクロマトグラフィーシステム
JP2022532795A (ja) ホスト細胞タンパク質の同定および定量方法
JP2018525408A (ja) アフィニティークロマトグラフィーにおける宿主細胞タンパク質の低減方法
EP3671200B1 (en) Ce-western applications for antibody development
HK40059237A (en) Multimeric protein purity determination
HK1252480B (en) Multimeric protein purity determination
ES3041610T3 (en) Systems and methods for affinity capillary electrophoresis
EP4136121B1 (en) Systems, materials, and methods for reversed-phase high performance liquid chromatography (rp-hplc) for monitoring formation of multi-specific molecules
HK40050332B (zh) 用於亲和毛细管电泳的系统和方法
BR112018001511B1 (pt) Uso de solução aquosa com baixa condutividade e métodos de produção e purificação de anticorpos de isotipo igg1 ou igg4 humano

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210506

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241028

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250221

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250225

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250423

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250423

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250702

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250702